Update shared on29 Aug 2025
Fair value Increased 75%The notable upward revision in P3 Health Partners’ price target is primarily supported by a significant decline in its forward P/E ratio, indicating improved earnings expectations, with the fair value estimate increased from $8.00 to $14.00.
What's in the News
- P3 Health Partners raised earnings guidance, projecting total revenues between $1.35 billion and $1.5 billion for fiscal 2025.
- The company was added to multiple Russell indices, including the Russell 3000E, Russell 3000E Growth, Russell 3000E Value, Russell Microcap, Russell Microcap Growth, and Russell Microcap Value indices.
Valuation Changes
Summary of Valuation Changes for P3 Health Partners
- The Consensus Analyst Price Target has significantly risen from $8.00 to $14.00.
- The Future P/E for P3 Health Partners has significantly fallen from 0.84x to 0.63x.
- The Discount Rate for P3 Health Partners has fallen slightly from 10.33% to 10.10%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.